Amneal launches Biosciences unit to market generic, specialty drugs

Amneal said on Tuesday that it has created Amneal Biosciences, a wholly owned subsidiary of Amneal Pharmaceuticals LLC.

Amneal Biosciences will focus on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals, such as injectables, oncologics and biosimilars.

“Having a dedicated company focused on the unique needs and logistics of this market segment allows Amneal to guarantee the same level of quality and service to health care institutions and professionals that we deliver to our existing retail customers,” Amneal Co-CEO and Chairman Chirag Patel said. “Amneal has a robust pipeline of both small-molecule injectable generics and biosimilars, and we expect to bring the first of these to market in early 2016. Our experienced Amneal Biosciences team provides the high degree of expertise these specialty products require.”

Charles Lucarelli will be heading Amneal Biosciences as president. Lucarelli joined Amneal in March after 37 years at Memorial Sloan Kettering Cancer Center, including 25 years as director of pharmacy.

“It is an honor to serve as president of Amneal Biosciences and lead this talented group of professionals at such a pivotal time in our company’s evolution,” Lucarelli said. “Our robust product pipeline will bring the Amneal legacy of quality and customer service to a segment in need of therapeutic affordability and reliable supply.”